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Abstract: The re-discovery of chiral monodentate ligands that 
was made in the 1999-2003 period had important consequences 
in enantioselective transition metal catalysis, such as the 
introduction of the A/B concept (i.e., use of monodentate ligand 
mixtures) and, later, a renewed interest in supramolecular 
ligands capable of ligand-ligand and ligand-substrate 
interactions.  This Personal Account summarizes the 
contributions made by our research group in this area in the 
period 2004-2015, which reflect quite well the above-mentioned 
developments. Within this area, we introduced some original 
concepts, such as: i) use of chiral tropos ligand mixtures; ii) 
development of new strategies to maximize the heterocomplex 
formation from combinations of simple monodentate ligands; iii) 
investigation of new ligand-ligand interactions to achieve 
selective heterocomplex formation; iv) development of highly 
efficient and synthetically accessible supramolecular ligands.  
1. Introduction 
It all started some twenty years ago when, at the end of a 
"Human Capital and Mobility" EC Network (1993-1996) where I 
served as the scientific coordinator, I passed the lead to 
Reinhard Hoffmann (Philipps-Universität Marburg), who 
successfully applied for a “Training and Mobility of Researchers” 
EC Network (1996-2000) called  "Combinatorial Approaches to 
Molecular Catalysts". In 2000, we renewed a successful 
application for an “Improving Human Potential” EC Network 
(2000-2004) called "The Discovery of New Catalysts through 
Combinatorial Chemistry: Activity and Selectivity from Diversity", 
with Albrecht Berkessel (Universität zu Köln) as coordinator. 
Under the strong leadership of Reinhard first and then Albrecht, 
we made the first steps in the Combicat field, which included 
combinatorial catalysis, parallel synthesis of libraries of chiral 
ligands, and high-throughput screening of the catalyst libraries. It 
was the time when Combinatorial Chemistry was being 
developed in the pharmaceutical world, and we investigated 
alternative aspects. Our first paper in this field, entitled 
“Combinatorial Libraries:  Studies in Molecular Recognition and 
the Quest for New Catalysts”, was published in Liebigs 
Ann./Recueil in 1997,[ 1 ] the year before merging into the 
European Journal of Organic Chemistry. In that period, our main 
focus was the investigation of new chiral ligands for 
enantioselective catalysis via parallel synthesis and high 
throughput screening of the ligand library.[2,3] 
New libraries containing hundreds of chiral ligands were 
designed and synthesized in parallel. A multisubstrate high-
throughput screening of the ligand library was realized by 
performing the reactions on an equimolar mixture of substrates 
and directly analyzing the reaction crudes for conversion and 
enantiomeric excess by gas chromatography with a chiral 
capillary column, under conditions where the 2n peaks of the n 
enantiomeric products showed baseline separation.[2e-j] From the 
screening of the ligand library, the best ligand was identified for 
a particular substrate. The results confirmed the value of the 
combinatorial approach: it would have been very difficult to 
identify the best ligand for a particular substrate if a “rational” or 
a “positional scanning” approach were followed for the ligand 
synthesis.[2] 
The field was reviewed in 2003 with a highly cited article 
“Combinatorial libraries of chiral ligands for enantioselective 
catalysis” in Chemical Reviews.[3] I like to mention the 
collaborations of that period, with Richard Jackson (The 
University of Newcastle and then the University of Sheffield from 
2001), Adriaan Minnaard and Ben Feringa (University of 
Groningen), Sergio Cenini and his group (University of Milan). I 
also like to mention a number of students and postdocs of that 
period, who later on embarked in an academic career: Umberto 
Piarulli (University of Insubria at Como), Isabelle Chataigner 
(Université de Rouen, Mont-Saint-Aignan), Sandrine Ongeri 
(Université Paris-Sud). 
At the end of this first decade, we shifted our focus towards the 
use of dynamic libraries of monodentate ligands in catalysis and 
of heteroleptic catalysts (i.e., obtained from mixtures of two 
ligands). This work – which was supported by another EC 
Research Training Network (2006-2010) called "(R)evolutionary 
Catalysis" and coordinated by Joost Reek (University of 
Amsterdam) – is described in the first part of this account 
(Paragraph 2).[ 4 , 5 , 6 , 7 , 8 ] During these studies, we became 
interested in supramolecular catalysis, and our contributions in 
this field – produced within the frame of the European Industrial 
Doctorate-Initial Training Network “REDUCTO” (2012-2016), 
coordinated by myself – are described in Paragraph 
3.[9,10,11,12,13,14] 
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2. Mixtures of monodentate ligands 
2.1. The A/B concept 
The “A/B concept” (Scheme 1) was independently proposed by 
Reetz and co-workers[ 15 ] and by Feringa, de Vries and co-
workers[16] in the early 2000s: it was shown that use of binary 
monodentate ligand mixtures (La and Lb) in the presence of a 
metal source (M = Rh in most cases) can lead to better catalytic 
activity and/or enantioselectivity than when the single ligands 
are employed. This outcome is observed when the 
heterocomplex [MLaLb] is more active and/or enantioselective 
than the corresponding homocomplexes [MLaLa] and [MLbLb]. 
Interestingly, in some cases, heterocomplexes in which one of 
the ligands is achiral ([ML*L]) are more enantioselective than the 
chiral ligand homocomplexes (ML*2]).
[15c,17] 
 
Scheme 1. The “A/B concept”: use of binary mixtures of monodentate ligands. 
The ligand mixture approach made a strong impact in the field of 
homogeneous catalysis, whose adepts were generally 
accustomed to deal with single and well-defined complexes. 
Moreover, the potential of this approach for combinatorial, high-
throughput catalyst screening became immediately evident. 
Indeed, using a relatively small pool of chiral ligands (n), a much 
bigger number of catalysts could be screened, spreading from n 
ligand homocombinations and [n • (n + 1) / 2] - n 
heterocombinations. The A/B concept rapidly found numerous 
applications in important reactions such as Rh-catalyzed 
asymmetric hydrogenation and conjugate addition, which were 
extensively reviewed by M. Reetz in 2008.[18] 
2.2. Mixtures of tropos ligands 
Our main contribution in this field consisted in applying the A/B 
concept to chiral tropos P-ligands, in which the substituents at 
the phosphorus atom are a chiral alkoxy or amino moiety and a 
‘flexible’ biphenol unit (Scheme 2 A).[ 19 ] Tropos P-ligands 
possessing the biphenol motif had been already employed by 
others in Cu-catalyzed reactions (enantioselective conjugate 
addition[ 20 ] and allylic substitution[ 21 ]), Rh-catalyzed 
transformations (olefin asymmetric hydrogenation[ 22 ] and 
hydroformylation [23]), but we were the first to use combinations 
of monodentate ligands belonging to this family. As a 
consequence of the free stereoaxis rotation, these ligands exist 
as mixtures of the rapidly interconverting diastereoisomers L and 
L’ (Scheme 2 B) and, in the presence of a metal with two free 
coordination sites, each ligand can form up to three complexes: 
[ML2], [ML’2] and [MLL’]. When two tropos monodentate ligands 
La and Lb are mixed in the presence of a metal, a sort of 
‘dynamic library’ of up to 10 complexes may be formed in situ 
(Scheme 2 C): [MLaLa], [MLaLa’], [MLa’La’], [MLbLb], [MLbLb’], 
[MLb’Lb’], [MLaLb], [MLaLb’], [MLa’Lb], [MLa’Lb’]. 
 
 
Scheme 2. Stereoaxis rotation in biphenol-derived tropos ligands (A); 
homocombinations (B) and heterocombinations (C) of tropos monodentate 
ligands in the presence of a metal. 
In principle, each of these species can catalyze a given reaction 
with a different level of stereoselectivity and stereochemical 
preference (R or S product). As a consequence, the overall 
observed stereochemical outcome is a sort of average weighted 
by the catalytic activity of each complex, with the most active 
complex(es) overriding the less active ones. We thus 
synthesized a library of nineteen biphenol-derived chiral tropos 
P-ligands (11 phosphites and 8 phosphoramidites), shown in 
Figure 1. 
 
 
          
 
 
 
 
 
 
Figure 1. Library of tropos phosphites (L1-L11) and phosphoramidites (L12-L19) employed by our research group in Rh-catalyzed reactions. 
Ligands L1-L19 and their combinations were screened in two 
different Rh-catalyzed reactions:[6] (i) the asymmetric 
hydrogenation of olefins[4] and (ii) the asymmetric conjugate 
addition of phenylboronic acids to cyclic enones.[5] 
The first hydrogenation screening was carried out using methyl 
2-acetamidoacrylate (S1) as a substrate (selected results in 
Table 1).[4] 
 
Table 1. Selected results in Rh-catalyzed hydrogenation of methyl 2-
acetamidoacrylate (1) using ligands L1-L19.
[a]
 
 
Entry L
a 
L
b 
Solv. Yield (%)
[b] ee (%),
[b]
 
abs. config. 
1 L3 L3 DCM 100 25, R 
2 L4 L4 DCM 80 53, S 
3 L5 L5 DCM 100 55, R 
4 L12 L12 DCM 7 52, R 
5 L13 L13 DCM 7 52, S 
6 L3 L13 DCM 40 73, S 
7 L4 L12 DCM 100 35, R 
8 L4 L13 DCM 100 87, S 
9 L4 L13 MeOH 100 88, S 
10 L4 L13 iPrOH 100 94, S 
11 L4 L13 AcOEt 100 91, S 
[a] Reaction conditions: ligands (0.002 mmol L
a
 and 0.002 mmol L
b
), 
[Rh(cod)2BF4] (0.002 mmol), 1 (0.2 mmol), solvent (2 mL), H2 (1 bar), r.t., 60 h. 
[b] Yields and ees determined by GC equipped with a chiral column.
[4a] 
 
Before using ligand mixtures (‘heterocombinations’), the ligands 
were screened individually (‘homocombinations’). As a general 
trend, phosphites (Table 1, entries 1-3) showed much higher 
catalytic activity than phosphoramidites (Table 1, entries 4-5), 
and both types of ligand gave moderate enantioselectivity (up to 
55% ee). No benefit derived from the use of phosphite/phosphite 
and phosphoramidite/phosphoramidite heterocombinations: the 
former gave full conversions and low enantioselectivity, and the 
latter gave low conversion and lower enantioselectivity than the 
corresponding single ligands. On the contrary, the 
phosphite/phosphoramidite combinations (Table 1, entries 6-11) 
led in several cases to a remarkable improvement of the 
enantioselectivity, while substantially retaining the high activity of 
the phosphite complexes. The best combination L4/L13 allowed 
to obtain (S)-N-acetylalanine methyl ester 2 with 100% yield and 
87% ee (Table 1, entry 8). The corresponding mismatched 
combination L4/L12 gave the (R)-product with only 35% ee 
(Table 1, entry 7), thus showing that the sense of stereocontrol 
is determined by the configuration of the phosphoramidite ligand. 
Use of polar solvents allowed to improve the enantioselectivity 
(Table 1, entries 9-11), and the best ee (94%) was obtained in 
iPrOH (Table 1, entry 10). Under these optimized conditions 
(iPrOH, 1 bar H2, r.t.), also N-acetamidoacrylic acid was 
hydrogenated with full conversion and 94% ee using the 
combination L4/L13. 
In collaboration with Prof. J. G. de Vries, Dr. A. H. M. de Vries, 
and Dr. L. Lefort (DSM Pharma Chemicals – Advanced 
Synthesis, Catalysis, and Development), we could carry out 
high-throughput ligand screening in hydrogenation using a 
Premex-96 multireactor.[4a]  
 
 
 
          
 
 
 
 
 
In the hydrogenation of methyl 2-acetamidocinnamate 3 
(selected results in Table 2) the scenario was quite similar to 
that observed with substrate 1: phosphites formed more active 
catalysts than phosphoramidites and the 
phosphite/phosphoramidite heterocombinations led to a 
remarkable improvement of the enantioselectivity (Table 2, entry 
3 vs. entries 1-2). 
 
Table 2. Selected results in Rh-catalyzed hydrogenation of methyl 2-
acetamidocinnamate (3) using ligands L1-L19.
[a]
 
 
Entry L
a 
L
b 
Solv. Yield (%)
[b] ee (%),
[b]
 
abs. config. 
1 L4 L4 DCM 100 64, S 
2 L13 L13 DCM 2 6, S 
3 L4 L13 DCM 82 85, S 
4
[c] 
L4 L13 iPrOH 100 95, S 
5 L5 L19 DCM 100 69, R 
6 L6 L19 DCM 100 64, R 
[a] Reaction conditions: ligands (0.0035 mmol L
a
 and 0.0035 mmol L
b
), 
[Rh(cod)2BF4] (0.0035 mmol), 3 (0.175 mmol), solvent (2.5 mL), H2 (10 bar), 
r.t., 16 h. [b] Yields and ees determined by GC equipped with a chiral 
column.
[4a]
 [c] H2 (5 bar). 
Also with 3, the combination L4/L13 gave the best results (Table 
2, entry 3). A solvent screening carried out in an autoclave 
multireactor (Agonaut EndeavorTM) led to identify iPrOH as the 
best solvent (100% yield, 95% ee, Table 2, entry 4). Switching to 
2-acetamidocinnamic acid (5) under optimized conditions (iPrOH, 
10 bar H2, r.t.) led to similar results (Table 3, entry 1), L4/L13 
being again the best ligand combination. However, improved 
enantioselectivity was obtained with substrates 6 and 7, chloro-
substituted derivatives of 2-acetamidocinnamic acid (Table 3, 
entries 2-3). 
Another ligand screening was carried out with methyl (Z)-3-
acetamidocrotonate (8), precursor of chiral β-aminoacids, which 
are pharmaceutical building blocks. With this substrate, L3/L19 
was identified as the best ligand combination, forming the (R)-
product with 71% ee (Table 3, entry 4). 
 
Table 3. Selected results in Rh-catalyzed hydrogenation of 2-
acetamidocinnamic derivatives (4-6) and methyl (Z)-3-acetamidocrotonate (7) 
using ligands L1-L19.
[a]
 
 
Entry Substrate
 
L
a 
L
b Yield 
(%)
[b] 
ee (%),
[b]
 
abs. conf. 
1 
5 
L4 L13 100 93, S 
2 
6 
L4 L13 100 98, S 
3
 
7 
L4 L13 100 97, S 
4
[c] 
8 
L3 L19 100 71, R 
[a] Reaction conditions: ligands (0.01 mmol L
a
 and 0.01 mmol L
b
), 
[Rh(cod)2BF4] (0.01 mmol), substrate (0.5 mmol), solvent (5 mL), H2 (10 bar), 
r.t., 16 h. [b] Yields and ees determined by GC equipped with a chiral 
column.
[4a]
 [c] Ligands (0.0035 mmol L
a
 and 0.0035 mmol L
b
), [Rh(cod)2BF4] 
(0.0035 mmol), substrate (0.175 mmol), solvent (2.5 mL), H2 (25 bar). 
Kinetic studies were carried by monitoring the H2 uptake of 
hydrogenation of substrates 1, 3 and 8 in the presence of the 
most efficient ligand heterocombination (L4/L13 for 1 and 3; 
L3/L19 for 8) and of the corresponding homocombinations 
(Figure 2).[4a] For substrate 1 (Figure 2 A), it was found that 
phosphite L4 forms a very fast Rh-catalyst, achieving full 
conversion (with 61% ee) in 12 minutes. On the contrary, the 
homocomplex of phosphoramidite L13 proved very sluggish, 
giving only 2% conversion (with 89% ee) after a few hours. The 
L4/L13 heterocombination – yet slightly less active than the L4-
homocomplex – showed good catalytic activity, giving full 
conversion and 94% ee in 20 minutes. This result clearly 
indicates that a Rh-complex containing both L4 and L13 was the 
most enantioselective species present in solution. As a 
consequence, maximizing the extent of heterocomplex formation 
was expected to lead to an increase of the enantioselectivity.  
 
Figure 2. Hydrogen uptake experiments (PH2 = 5 bar; solvent: iPrOH). A: substrate = methyl 2-acetamidoacrylate (1), ligand(s) = L4 (♦), L13 (■) and 1:1 L4/L13 
(▲); B: substrate = methyl 2-acetamidocinnamate (3), ligand(s) = L4 (♦), L13 (■) and 1:1 L4/L13 (▲); C: substrate = methyl (Z)-3-acetamidocrotonate (7), 
ligand(s) = L3 (▲), L19 (●) and 1:1 L4/L19 (♦). 
          
 
 
 
 
 
We reasoned that decreasing the L4/L13 ratio (while keeping 
the 2:1 [L4 + L13]/Rh ratio constant) would allow to enhance the 
amount of L4/L13-heterocomplex and L13-homocomplex 
formed, at the expense of the L4-homocomplex. As the L13-
homocomplex is a very sluggish catalyst, it should not negatively 
affect the overall observed enantioselectivity, which instead 
would benefit from the enhanced amount of heterocomplex. 
Delightfully, when a 0.25:1.75 L4/L13 ratio was used, the 
hydrogenation of 1 occurred with 100% yield and 98% ee. We 
carried out several other experiments varying the L4/L13 ratio 
(Figure 3, curve A), which confirmed that 0.25:1.75 is the optimal 
ratio between the two ligands. 
 
 
Figure 3. Dependence of the product ee on the phosphite/phosphoramidite 
ratio in the hydrogenation of: A (●): methyl 2-acetamidoacrylate 1 (PH2 = 5 bar, 
ligands = L4/L13); B (♦): methyl 2-acetamidocinnamate 3 (PH2 = 5 bar, ligands 
= L4/L13); C (■): methyl (Z)-3-acetamidocrotonate 7 (PH2 = 25 bar, ligands = 
L3/L19). Solvent = iPrOH. 
The H2 uptake profiles in the hydrogenation of methyl 2-
acetamidocinnamate 3 (Figure 2 B) are analogous to those 
observed with substrate 1 (Figure 2 A): the L4 homocomplex 
showed high catalytic activity (full conversion and 79% ee in 30 
minutes) and the L13 homocomplex was very sluggish (only 2% 
conversion and 36% ee), while the 1:1 L4/L13 
heterocombination gave full conversion and 95% ee in 2 h. Also 
in this case, experiments carried out with different ligand ratios 
(while keeping the 2:1 [L4 + L13]/Rh ratio constant) showed that 
the highest ee (98%) is obtained with a 0.25:1.75 L4/L13 ratio 
(Figure 3, curve B), although at the cost of a lower conversion 
(79%). Therefore, with these examples we demonstrated that 
the ee obtained from binary ligand mixtures which are more 
enantioselective than the corresponding homocomplexes can be 
enhanced by carefully adjusting the La:Lb ratio, provided that at 
least one of the homocomplexes is remarkably less active than 
the heterocomplex. As can be seen in Figure 2 C, the latter 
requirement was not satisfied in the case of the hydrogenation of 
methyl (Z)-3-acetamidocrotonate 8 with ligands L3 and L19. 
Indeed, in this case the two Rh-homocomplexes were both more 
active than the heterocomplex (which was the most 
enantioselective species): as demonstrated by our experiments 
with different L3/L19 ratios (Figure 3, curve C), in this case the 
optimal ligand ratio is 1:1, which statistically favors the formation 
of the heterocomplex over the homocomplexes. 
We tested our tropos ligands L1-L19 (Figure 1) also in the Rh-
catalyzed asymmetric conjugate addition of arylboronic acids to 
cyclic enones,[ 24 ] to which chiral monophosphoramidites had 
been recently applied with success by Feringa and co-
workers.[ 25 ] The reaction of phenylboronic acid with 2-
cyclohexenone 10 was carried out in the presence of 1.5 mol% 
of [Rh(C2H4)2Cl]2 and 6 mol% of ligand(s) (Rh/L = 1:2).
[5,6] The 
reaction was carried out in a 10:1 dioxane/H2O mixture at r.t. in 
the presence of KOH (1 equiv.) as base.[26] Selected results of 
this screening are shown in Table 4.  
 
Table 4. Selected results from the screening of the L1-L19 library (homo- and 
heterocombinations) in the Rh-catalyzed conjugate addition of phenylboronic 
acid to cyclic enones.
[a]
 
 
Entry Enone
 
L
a 
L
b 
Yield (%)
[b] 
ee (%),
[b] 
abs. conf. 
1 10 L6 L6 100 70, R 
2 10 L9 L9 100 28, R 
3
 
10 L18 L18 100 36, S 
4
 
10 L19 L19 100 36, R 
5 10 L6 L19 100 95, R 
6 10 L9 L19 100 91, R 
7 10 L6 L18 100 70, S 
8 10 L9 L18 100 87, S 
9 11 L9 L18 100 80, S 
10 11 L2 L18 80 83, S 
11 11 L6 L19 100 90, R 
12 11 L9 L19 100 90, R 
13 9 L7 L7 100 58, S 
14 9 L6 L19 100 73, R 
15 9 L9 L19 100 68, R 
[a] Standard reaction conditions: (L
a
 + L
b
)/[Rh(C2H4)2Cl]2/PhB(OH)2/KOH/ 
substrate =  0.06:0.015:2:1:1. [b] Yields and ees determined by GC equipped 
with a chiral column.
[5a] 
As a general trend, when the ligands were used individually 
(homocombinations), phosphites (L1-L11) formed more active 
and enantioselective complexes than phosphoramidites (L12-
L19). However, the enantioselectivities were moderate, the best 
ee (70%) being obtained with ligand L6 (Table 4, entry 1). Most 
of the ligand mixtures screened formed catalysts less active and 
enantioselective compared to phosphite homocomplexes, with 
the remarkable exception of the phosphite/phosphoramidite 
combinations containing either L18 or L19 (Table 4, entries 5-
15). These heterocombinations gave full conversion and 
remarkably higher enantioselectivities compared to the 
corresponding homocomplexes: the combinations L6/L19 and 
L9/L19 allowed to obtain (R)-3-phenylcyclohexanone (13) with 
95% and 91% ee, respectively (Table 4, entries 5-6). As in the 
above-discussed hydrogenation, the corresponding mismatched 
          
 
 
 
 
 
combinations L6/L18 (Table 4, entry 7) and L9/L18 (Table 4, 
entry 8) showed opposite stereochemical preference [(S)- 
instead of (R)-13], thus proving that it is the phosphoramidite 
which determines the absolute configuration of the reaction 
product. The effect of substrate’s ring size was assessed by 
screening all the homocombinations and several 
heterocombinations with 2-cyclopentenone (9) and 2-
cycloheptenone (11). Also with these substrates, the 
heterocombinations containing the 2,5-diphenylpyrrolidine 
phosphoramidites L18 and L19 gave the best results: in 
particular, the matched combination L6/L19 afforded the 
products (R)-12 and (R)-14 with 90% and 73% ee, respectively 
(Table 4, entries 11 and 14). 
 
 
Figure 4. Variable-temperature 
31
P NMR experiments. A: homocomplex 
L19/[Rh(acac)(C2H4)2]; B: heterocombination L6/L19/[Rh(acac)(C2H4)2]. Marks 
above the peaks allow the identification of the different complexes. 
Although such terms as “induced atropoisomeric”[20b] and 
“fluxionally atropoisomeric”[17c] had been used for metal 
complexes of biphenolic tropos ligands, as of 2005 no in-depth 
study of their tropos or atropos behavior had been reported. 
Thus, we were among the first to carry out such investigation,[27] 
which was performed by variable-temperature 31P NMR 
spectroscopy.[5] In particular, we studied the dynamic behavior of 
the two best performing ligands (phosphite L6 and 
phosphoramidite L19) and of their homo- and 
heterocombinations in the presence of [Rh(acac)(C2H4)2]. The 
free ligands were studied over the temperature range 380-180 K. 
Above 210 K, one singlet peak was always observed, indicating 
a free rotation of the biaryl bond (tropos behavior). Below this 
temperature, the signal broadened and eventually split in two 
signals with coalescence temperatures (TC) between 200 K and 
180 K. In the case of ligand L6, we observed TC = 197 K, 
corresponding to a free energy barrier for biphenol rotation ΔG‡ 
= 8.5 kcal mol-1. The Rh-complexes were studied over the 
temperature range 380-230 K, as it was not possible to cool 
below 230 K due to solubility issues. Within this range, the L6 
homocomplex always gave a doublet signal, denoting a tropos 
behavior. On the contrary, the L19 Rh-homocomplex displayed 
a typical coalescence behavior (TC = 320 K in [D]8toluene; TC = 
290 K in CD2Cl2). As shown in Figure 4 A, below the TC, the 
originally observed doublet signal split in one doublet (), 
corresponding to the complexes {Rh[(aR)-L19]2} and {Rh[(aS)-
L19]2} – in which the P-ligands are homotopic – and two doublet 
doublets (), corresponding to the complex {Rh[(aR)-L19][(aS)-
L19]} – in which the P-ligands are diastereotopic. The L6/L19 
heterocombination treated with [Rh(acac)(C2H4)2] (Figure 4 B), 
besides the above-described homocomplex signals ( and ▲, ca. 
40% of total integration), showed other signals () which can be 
assigned to a heterocomplex [Rh(L6)(L19)] (ca. 60% of total 
integration): at 375 K, two doublet doublets were observed, 
corresponding to a tropos behavior of both L6 and L19. These 
signals coalesced at 310 K and, by further cooling to 230 K, a 
new system of two doublet doublets appeared. The latter was 
assigned as one of the possible diastereoisomers that can be 
obtained when L19 is atropos while the stereoaxis of L6 is still 
free to rotate (tropos): {Rh(L6)][(aR)-L19]} or {Rh(L6)][(aS)-L19]}. 
The free energy barrier for phosphoramidite biphenol rotation in 
[D8]toluene (TC = 310 K) was calculated: ΔG
‡ = 14.5 kcal mol-1. 
To guess the configuration of the L19 stereoaxis in this complex, 
we synthesized ligands L20 and L21 (Scheme 3) – (S)- and (R)-
BINOL-derived analog of L19, respectively – and we used them 
in combination with L6 in our test reaction on 2-cyclohexenone. 
However, surprisingly these combinations were less effective 
than L6/L19 [50% yield, 46% ee (R) with L6/L20; 70% yield, 
72% ee (R) with L6/L21], thus emphasizing the peculiar 
properties of a tropos/atropos biphenol moiety near the 
coalescence temperature. 
 
 
Scheme 3. Rh-catalyzed enantioselective addition of arylboronic acids to N-
tosylarylimines.
[7] 
In the attempt to further expand the application scope of our 
chiral tropos ligands, we investigated the Rh-catalyzed addition 
          
 
 
 
 
 
of arylboronic acids to N-tosylarylimines.[7] However, in this 
transformation the use of ligand mixtures did not bring any 
significant benefits, and the best results were obtained with the 
atropos phosphoramidites L20-22 (Scheme 3). 
Recently, in collaboration with Dr. L. Lefort and Prof. J. G. de 
Vries, we used a mixed ligand strategy in the asymmetric 
hydrogenation of 2-substituted N-benzylated pyridinium salts. A 
catalyst formed in situ from [Ir(cod)Cl]2, a chiral monodentate 
phosphoramidite and an achiral phosphine, allowed to obtain the 
corresponding N-benzyl-2-aryl-piperidines with full conversion 
and good enantioselectivity (up to 82% ee).[17a] 
2.3. Maximizing the amount of heterocomplex 
Our interest in chiral monodentate ligands and their 
combinations led us to investigate new methods to maximize the 
formation of the heterocomplexes [MLaLb] at the expense of the 
corresponding homocomplexes [MLaLa] and [MLbLb]. Indeed, 
when the heterocomplex is more enantioselective than the 
homocomplexes, the statistical distribution 2:1:1 
[MLaLb]/[MLaLa]/[MLbLb] leads to erosion of the overall 
enantioselectivity, unless the catalytic activity of [MLaLb] is much 
higher than that of [MLaLa] and [MLbLb]. Whereas most of the 
strategies to achieve selective heterocomplex formation rely on 
supramolecular ligands (see Paragraph 3), we also pursued a 
different approach, which consists in combining simple 
monodentate ligands with complementary electronic 
properties.[8] We reasoned that electronically matching ligands, 
such as a π-acceptor phosphite and a σ-donor phosphine, could 
selectively form the heterocomplex owing to its higher stability 
compared to the homocomplexes. To test this hypothesis, we 
carried out a preliminary computational study (DFT calculations 
at the B3LYP/SDD level of theory), showing that the 
triphenylphosphite/triphenylphosphine Rh-heterocomplex is 
more stable than the corresponding homocomplexes by 5.11 
kcal mol-1 (Scheme 4 A).  
 
 
Scheme 4. DFT study on the relative stability of heterocomplexes vs. 
homocomplexes (B3LYP/SDD level of theory). A: a phosphite/phosphite 
heterocombination. B: a phosphite/phosphinamine heterocombination. 
Consistent with this theoretical result, when [Rh(acac)(C2H4)2] 
was added to a 1:1 mixture of phosphite L23 (Figure 5) and 
PPh3, 94:6 heterocomplex/homocomplexes selectivity was 
observed by 31P NMR spectroscopy, the heterocomplex giving a 
set of two doublet doublet signals (Figure 6 A). We aimed at 
applying this approach to chiral ligand mixtures, but chiral 
monophosphines are not readily available nor easy to make. 
Therefore we envisaged phosphinamines as a possible 
replacement for phosphines. Indeed, chiral phosphinamines can 
be easily prepared from readily available chiral amines, while 
retaining σ-donor properties similar to those of phosphines. DFT 
calculations showed that the triphenylphosphite/(R)-N,N-
dimethyl-1,1-diphenylphosphinamine heterocomplex is more 
stable than the corresponding homocomplexes by 11.29 kcal 
mol-1 (Scheme 4 B). 
We thus synthesized a small library of chiral phosphites (L23-
27), derived from BINOL, and phosphinamines (L28-34), which 
are shown in Figure 5. 
 
Figure 5. Chiral phosphites (L23-27) and phosphinamines (L28-34) used for 
π-acceptor/σ-donor heterocombinations. 
The formation of phosphite/PPh3 and of 
phosphite/phosphinamine heterocomplexes in the presence of 
[Rh(acac)(C2H4)2] was investigated by 
31P NMR spectroscopy. 
When either PPh3 (Figure 6 A) or C1-symmetric phosphinamines 
(L30-34) were combined with a BINOL-phosphite, the 
heterocomplexes were formed with selectivities ranging from 
70% to ≥ 99%, as in the case of combination L25/L30 (Figure 6 
B). 
 
Figure 6. 
31
P NMR study on the formation of Rh-heterocomplexes (CD2Cl2). A: 
1:1:1 PPh3/L23/[Rh(acac)(C2H4)2] (94:6 heterocomplex/homocomplexes). B: 
A: 1:1:1 L30/L25/[Rh(acac)(C2H4)2] (99:1 heterocomplex/homocomplexes). 
          
 
 
 
 
 
Homo- and heterocombinations of ligands L23-34 were tested in 
the asymmetric hydrogenation of methyl 2-acetamidoacrylate 1 
and N-(1-phenylvinyl)acetamide 15 (selected results are shown 
in Table 5). 
 
Table 5. Selected results in Rh-catalyzed hydrogenation of methyl 2-
acetamidoacrylate (1) and N-(1-phenylvinyl)acetamide (15) using ligands L23-
L30.
[a]
 
 
Entry Substrate L
a 
L
b Yield 
(%)
[b] 
ee (%),
[b]
 
abs. config. 
1 1 L25 L25 100 96, S 
2 1 L30 L30 52 12, S 
3 1 L33 L33 57 12, R 
4 1 L25 L30 87 60, R 
5 1 L25 L33 48 40, R 
6 15 L25 L25 100 92, S 
7 15 L30 L30 83 7, R 
8 15 L33 L33 74 7, S 
9 15 L25 L30 99 57, R 
10 15 L25 L33 96 38, R 
[a] Reaction conditions: ligands (0.0077 mmol L
a
 and 0.0077 mmol L
b
), 
[Rh(cod)2BF4] (0.007 mmol), substrate (0.7 mmol), DCM (8 mL), H2 (1 bar with 
subst. 1, 5 bar with subst. 15), r.t., 16 h. [b] Yields and ees determined by GC 
equipped with a chiral column.
[8] 
With both substrates, phosphinamines behaved poorly, giving 
low conversions and ees (Table 5, entries 2-3 and 7-8). 
Remarkably, the heterocombinations L25/L30 and L25/L33 
showed opposite stereochemical preference than the 
corresponding homocombinations (Table 5, entry 4 vs. 1 and 2; 
entry 10 vs. 6 and 8), consistent with the heterocomplex being 
the main catalyst in the reaction environment. Unfortunately, 
both activity and enantioselectivity of these heterocomplexes 
were lower than those of phosphite homocomplexes. Ligands 
L25, L30 and L33 were tested also in Pd-catalyzed asymmetric 
allylic substitution, giving again a peculiar stereochemical 
outcome but no improvement in terms of enantioselectivity.[8] 
Although the catalytic results were somehow disappointing, to 
the best of our knowledge this was the first report in which the 
importance of using electronically matching ligands to maximize 
the heterocomplex formation is clearly discussed. In other 
contributions, this effect is given limited[28] or no emphasis,[29] 
whereas the selective heterocomplex formation is mostly 
attributed to supramolecular interactions. 
3. Supramolecular ligands 
In the last 10-15 years, the interest for the development of new 
supramolecular ligands – i.e. ligands possessing, besides the 
donor atom(s) required for metal coordination, a functional group 
capable of non-covalent interactions – has grown significantly.[30] 
Such non-covalent interactions can occur between ligands, 
leading to formation of the so-called ‘supramolecular bidentate 
ligands’ (Scheme 5 A and B), or between ligand(s) and substrate 
(Scheme 5 C), giving rise to a substrate orientation effect similar 
to the one exerted by metalloenzymes. In particular, the 
formation of complementary interactions between ligands can 
allow the selective or exclusive formation of heteroleptic 
complexes from ligand mixtures (Scheme 5 A), thus overcoming 
an intrinsic limitation of the mixed ligand approach (see 
Paragraph 2.3). For this reason, since 2002-2003 several 
groups started developing chiral monodentate ligands capable of 
different kinds of non-covalent interactions. 
 
 
Scheme 5. Non-covalent interactions for the formation of heterocomplexes (A), 
for the formation of heterocomplexes (B), and for substrate coordination (C). 
In this context, after exploring the strategies described in 
Paragraph 2 (i.e., variation of the ligand ratio and use of 
electronically matching ligands) to maximize the formation of 
monodentate ligand heterocomplexes, we also pursued the 
supramolecular approach.  
Our first attempt in this sense was the development of BINOL-
phosphites bearing either an electron-rich (methoxyarene) or an 
electron-poor (perfluoroarene) substituent,[9] with the aim to 
achieve preferential formation of the Rh-heterocomplexes by 
means of π-π interactions.[31] Unfortunately, although in some 
cases the ligand heterocombinations gave better ees (up to 99% 
ee) than the corresponding homocombinations in olefin 
hydrogenation, no selective formation of Rh-heterocomplexes 
could be detected by 31P NMR.  Thus, π-π interactions turned 
out to be too weak (in solution) to drive the equilibrium towards 
the heterocomplexes. 
3.1. Acid-base interactions 
In 2008, we set to investigate an alternative approach to the 
selective formation of heterocomplexes relying on ionic 
interactions. Indeed, we reasoned that the electrostatic 
interaction between ligands bearing opposite charge could shift 
the equilibrium towards the heterocomplexes, as it had just been 
preliminarily shown (although with no catalytic applications) by 
van Leeuwen and co-workers.[ 32 ] Our strategy consisted in 
          
 
 
 
 
 
combining ligands bearing an acidic and a basic group, 
respectively, which would react forming the desired ion pair. To 
this end, a small library of BINOL-phosphites bearing a 
carboxylic acid and a tertiary amino group, respectively, was 
synthesized (selected examples are shown in Figure 7).[10] 
 
Figure 7. Selected examples from our library of acidic (L35-36) and basic 
BINOL-phosphites (L37-L38).
[10] 
Acidic and basic phosphites were combined in the presence of 
[Rh(acac)(C2H4)2] and the formation of Rh-complexes was 
monitored by 31P NMR, while the formation of the amine-
carboxylic acid salt was verified by IR. Unfortunately, only 
moderate selectivity for the heterocomplexes was observed (up 
to 70:30 heterocomplex/homocomplexes). Homo- and 
heterocombinations of acidic and basic ligands were tested in 
the hydrogenation of methyl 2-acetamidoacrylate 1, and in some 
cases enhanced ees were obtained with the heterocombinations 
(Table 6). 
 
Table 6. Selected results in Rh-catalyzed hydrogenation of methyl 2-
acetamidoacrylate (1) using acidic and basic BINOL phosphites L35-38.
[a]
 
 
Entry L
a 
L
b 
Yield (%)
[b] 
ee (%),
[b]
 abs. config. 
1 L35 L35 100 80, S 
2 L36 L36 100 80, S 
3 L37 L37 100 84, S 
4 L38 L38 30 86, S 
5 L35 L38 100 90, S 
6 L36 L38 100 88, S 
[a] Reaction conditions: ligands (0.0077 mmol L
a
 and 0.0077 mmol L
b
), 
[Rh(cod)2BF4] (0.007 mmol), 1 (0.7 mmol), DCM (1 mL), H2 (1 bar), r.t., 24 h. 
[b] Yields and ees determined by GC equipped with a chiral column.
[10]
 
Although low selectivity in the heterocomplex formation was 
achieved, to the best of our knowledge this is the first use of 
ligand-ligand ion-pairing interactions for a catalytically relevant 
complex.[33] 
3.2. Hydrogen bonding interactions 
After the seminal contribution by Breit and Seiche in 2003,[34o] 
hydrogen bonding has rapidly become the most studied and 
exploited non-covalent interaction for achieving the formation of 
‘supramolecular bidentate ligands’ from both ligand 
homocombinations[34] and heterocombinations.[29b-c, 35 ] This 
success is due to the easy synthesis and stability of several 
functional groups capable of hydrogen bonding and to the fact 
that hydrogen bonds can form dynamically and reversibly in the 
environment where catalysis is to take place, without need to 
preliminarily prepare the ligand-ligand assembly. As shown in 
Scheme 5 A, only when the ligand-ligand interaction is 
complementary, it is possible to selectively form the 
heterocomplexes from binary ligand mixtures.[30g,35] However, 
also the ligand-ligand assemblies formed from non-
complementary interactions (Scheme 5 B) can warrant 
enhanced catalytic performances – compared to simple 
monodentate ligands – because their complexes are rigid and 
conformationally restricted as those of bidentate ligands.[30g,34] 
In 2010 we reported a new family of BINOL-phosphites, named 
PhthalaPhos, bearing a bis-phthalamide residue able to act both 
as a donor and as an acceptor of hydrogen bond in non-
complementary interactions.[12] Owing to the modular structure 
(see Figure 8) and easy preparation of these ligands (4 steps 
from phthalic anhydride), we could synthesize a small library of 
19 representatives, differing from each other in: i) the 3,3’-
substitution of the BINOL moiety; ii) the ancillary amide residue 
(i.e., the one not bearing the phosphite); iii) the linker between 
the two units. 
 
 
Figure 8. General structure of the PhthalaPhos ligands with possible sites of 
diversity. 
The library was screened in the Rh-catalyzed hydrogenation of 
several pro-chiral substrates including dehydroamino esters, N-
acyl enamides and α,β-unsaturated esters. Consistent with the 
expected role of the phthalamide residue, both size/geometry of 
the linker connecting the phosphite group to it, and the ancillary 
amide group strongly influenced yield and enantioselectivity 
(highly diverse results were obtained throughout the library).[12] 
The best results are shown in Table 7: benchmark substrates 1, 
3 and 15 could be hydrogenated with nearly full 
enantioselectivity. Remarkably, outstanding ee values (96% and 
99%, respectively) were obtained also with the challenging 
substrates 17 and 18, precursors of industrially relevant chiral 
building blocks. The ee obtained with 18 was the highest ever 
reported for this substrate at that time. Notably, almost in all 
cases the simple monophosphites L49 and L50, devoid of the 
phthalamide moiety, gave lower ee and/or yield compared to the 
best PhthalaPhos ligand. 
NMR, IR and computational experiments (DFT) carried out on a 
representative ligand (L42, Table 7) and on its Rh-complex 
[Rh(cod)(L42)2BF4] allowed to confirm that, in this pre-catalytic 
          
 
 
 
 
 
complex, two hydrogen bonds are present between the coordinated ligands’ phthalamide groups (Figure 9).[12b] 
Table 7. Selected results from the screening of the PhthalaPhos and BenzaPhos library in the Rh-catalyzed asymmetric hydrogenation of olefins.
[a] 
Substrate 
PH2 1 
1 bar 
3 
1 bar 
15 
5 bar 
17 
20 bar 
18 
50 bar 
Best PhthalaPhos 
ligand 
L39  L40 L41 L42  L43 
ee, abs. conf.
[b] > 99%, R 99%, R 99%, R 96%, R 99%, R 
Best BenzaPhos 
ligand 
L44 L45 L46 L47 L48 
ee, abs. conf.
[b]
 99%, R > 99%, R > 99%, R > 99%, R > 99%, R 
Reference ligand 
L49 L49 L49 L49 L49 
ee, abs. conf.
[b]
 84%, R 70%, R 90%, R 53%,
[c]
 R 32%,
[c]
 R 
Reference ligand 
L50 L50 L50 L50 L50 
ee, abs. conf.
[b]
 90%, R 83%, R 94%, R 96%,
[d]
 R 90%,
[c]
 R 
[a] Reaction conditions: substrate/ligand/[Rh(cod)2BF4] = 100:2.2:1, solvent = DCM, c0 (substrate) = 0.024 M, T = 25 °C, 24 h. [b] Yields and ees determined by 
GC equipped with a chiral column.
[12,13]
 Yield = 100% in all cases, unless otherwise stated. [c] Yield < 50%. [d] Slower kinetics compared to L42. 
Thus, in the pre-catalytic complex the two coordinated 
molecules of L42 behave as a ‘supramolecular bidentate ligand’.  
 
 
Figure 9. DFT-calculated structure of the pre-catalytic complex 
[Rh(L42)2(cod)BF4] (wires and tubes: grey = C, red = O, blue = N, magenta = 
P; CPK spheres: blue = Rh). 
However, the results of several control experiments carried out 
using modified versions of ligand L42 and of the hydrogenation 
substrates demonstrate that, in the hydrogenation catalytic cycle, 
the role played by the phthalamide group is different,[12a] and 
probably consists in a substrate orientation effect.[36] We built the 
computational model of a conceivable intermediate of the 
catalytic cycle (Figure 10 A, substrate: 17, ligand: L42) where a 
hydrogen bond between an amide oxygen of L42 and the 
substrate’s NH is present. 
 
 
Figure 10. DFT-optimized structures of dihydride intermediates of the Rh-
catalyzed hydrogenation of 17 in the presence of ligand L42 (A) and L47 (B), 
respectively [wires (P-ligands) and tubes (substrate 17): grey = C, light grey = 
amide H atoms, black = heteroatoms (N, O, P); CPK spheres: black = Rh, grey 
= H. All H atoms bound to carbon are omitted]. 
As the outstanding performances of the PhthalaPhos ligands 
seemed to be due to their ability to form a single hydrogen bond 
with the reaction substrate, we reasoned that their structure 
could be further simplified by replacing the phthalamide residue 
with a simple benzamide. In this way, we created a new library 
          
 
 
 
 
 
of ligands (Figure 11), called BenzaPhos, which could be 
prepared in only two steps from commercially available 
compounds.[13] 
 
 
Figure 11. General structure of the BenzaPhos ligands with possible sites of 
diversity. 
Owing to the modular structure and trivial synthesis of these 
ligands, the following approach was adopted for ligand synthesis, 
screening and optimization in Rh-catalyzed hydrogenation: firstly, 
a 13-member library of ligands bearing an unsubstituted 
benzamide group and differing in the linker was prepared and 
screened with several pro-chiral olefin substrates. Once some 
hits were identified, structural modifications were introduced in 
the benzamide group of the best three ligands, and a small 
second-generation library was created, which gave improved 
results with some substrates.[13] The BenzaPhos ligands showed 
a scope similar to PhthalaPhos and also in this case, for each 
substrate, yields and ee values widely ranged from ligand to 
ligand. The best ligands (shown in Table 7) gave outstanding 
results (99% or > 99% ee) with substrates 1, 3, 15 and 18, and 
the ee obtained with substrate 17 (> 99%) was the best ever 
reported. 
Control experiments (with modified versions of ligand L47 and of 
substrate 17) analogous to those carried out with the 
PhthalaPhos ligands suggest that, in the catalytic cycle, the role 
of the bezamide group consists in coordinating the substrate. A 
computational model of a catalytic cycle intermediate was built 
(Figure 10 B), where a hydrogen bond between the ligand and 
the substrate’s NH is present. 
Recently, we have started testing the PhthalaPhos ligands in 
other transition metal-catalyzed reactions, obtaining some 
interesting results in Pd-catalyzed asymmetric allylic alkylation 
(AAA) reactions.[37] We investigated the synthesis of two types of 
chiral alkaloid scaffolds – 1-vinyltetrahydroisoquinoline[14b] and 4-
vinyltetrahydrocarbazole[14a] – by cyclization of suitable allylic 
carbonates. 
 
 
Figure 12. Phosphite L51, best ligands in the synthesis of 1-
vinyltetrahydroisoquinoline (20) and 4-vinyltetrahydrocarbazole (22) by Pd-
catalyzed intramolecular AAA. 
For both these reactions, phosphite L51 (Figure 12) turned out 
to be the best ligand, and thus was used for reaction 
optimization. For the synthesis of 1-vinyltetrahydroisoquinoline 
20,[14b] optimization of the reaction parameters led to identify 
toluene as the best solvent and 0 °C as the temperature 
ensuring the best compromise between catalytic activity and 
enantioselectivity. 
 
Table 8. Synthesis of 1-vinyltetrahydroisoquinoline 20 by Pd-catalyzed of 
allylic carbonates under optimized conditions.
[a]
 
 
Entry Substrate
 
t (h)
 
Conv. (%)
[b] 
ee (%),
[c]
 abs. config. 
1 (E)-19a 16 100 73, R 
2 (Z)-19a 104 100 62, R 
3 (E)-19b 44 100 83, R 
[a] Reaction conditions: substrate/L51/[Pd2(dba)3•CHCl3] = 100:10.5:2.5, 
solvent = toluene, c0 (substrate) = 13.9 mM, T = 0 °C. [b] Conversions 
determined by 
1
H NMR analysis of the crude reaction mixture. [c] ees 
determined by GC equipped with a chiral column.
[14b]
 
Under these conditions, it was found that the same enantiomer 
of product 20 (R) is obtained preferentially, irrespective of the 
double bond configuration of substrate 19a (Table 8, entries 1 
and 2). However, the cyclization of (Z)-19a was slower and gave 
slightly lower ee than that of (E)-19a. Moreover, increasing the 
size of the leaving group led to a notable increase of the 
enantioselectivity (Table 8, entry 3). Also the nature of the 
nucleophile strongly affected the reaction outcome: when the Ts 
group was replaced with COCF3, the reaction became sluggish 
(104 h at r.t. required for full conversion) and poorly 
enantioselective (9% ee).[14b] 
Contrary to the previous reaction, in the synthesis of 4-
vinyltetrahydrocarbazole 22 the best results were obtained in 
different solvents when (E)- and (Z) -21 were used as substrate 
(Table 9), and no benefit was obtained from using a bulkier 
leaving group nor from running the reaction at low 
temperature.[14a] Moreover, full conversions could be obtained 
with a 1 mol% catalyst loading. 
 
Table 9. Synthesis of 4-vinyltetrahydrocarbazole 22 by Pd-catalyzed of allylic 
carbonates under optimized conditions.
[a]
 
 
Entry Substrate
 
Solvent Conv. (%)
[b] ee (%),
[c]
 abs. 
config. 
1 (E)-21 toluene 100 70, S 
2 (Z)-21 DCM 100 75, R 
[a] Reaction conditions: substrate/L51/[Pd(OAc)2] = 100:2.1:1, c0 (substrate) = 
15 mM, T = 25 °C. [b] Conversions determined by 
1
H NMR analysis of the 
crude reaction mixture. [c] ees determined by GC equipped with a chiral 
column.
[14a]
 
          
 
 
 
 
 
Moreover, compared to the 1-vinyltetrahydroisoquinoline 
synthesis, a different stereochemical outcome was observed 
(Table 9):[14a] under the optimized conditions (1 mol% catalyst, 
r.t.), substrate (E)-21 formed preferentially product (S)-22 (70% 
ee), while (Z)-21 led to (R)-22 with 75% ee. This kind of 
stereodivergent behavior is precedented in the literature,[38] and 
should be a consequence of the slow equilibration (compared to 
the cyclization step) of the diastereomeric π-allyl-Pd complexes 
generated by oxidative addition of the catalyst to either the (E)- 
or the (Z)-allylic carbonates 21.[39] 
4. Summary and outlook 
The revival of chiral monodentate ligands that took place in the 
1999-2003 period opened up new perspectives for the search of 
new enantioselective transition metal catalysts. This shift of 
paradigm put in question the generally accepted idea that only 
chiral bidentate ligands can secure high enantioselectivity, and 
set the scene for the ligand mixture approach (2003-2004), 
which has been increasingly exploited in the next years, until 
present.[17a,40] In their turn, the intrinsic limitations of using ligand 
mixtures (i.e., mainly, co-formation of homocomplexes and 
heterocomplex) aroused a renewed interest in supramolecular 
ligands. However, it was soon understood that the 
supramolecular approach has a potential going beyond the mere 
selective formation of heteroleptic complexes, and covering also 
substrate activation by means of ligand-substrate interactions. 
Our contributions in this area in the 2005-2015 period, 
summarized in this Personal Account, reflect these 
developments quite well: we started from ligand mixtures to 
approach supramolecular catalysis (initially as a means to 
achieve selective heterocomplex formation and then as a 
substrate activation strategy). Doing so, we introduced some 
original aspects, such as: i) using chiral tropos ligand mixtures; 
ii) varying the La/Lb ratio and combining electronically matching 
ligands to maximize the heterocomplex formation; iii) 
investigating the use of ligand-ligand interactions to achieve 
selective heterocomplex formation; iv) developing highly efficient 
supramolecular ligands which are also structurally simple and 
synthetically accessible. 
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